Waltham, MA 12/15/16; Lyon, France 12/15/16—Bioprocessing technology firm Repligen has acquired TangenX Technology from Novasep for $39 million in cash. TangenX provides the single-use Sius line of tangential flow filtration (TFF) cassettes and hardware for downstream biopharmaceutical processing. Repligen expects the company to grow double digits and to add $7.0–$7.5 million to 2017 revenues. “This strategic acquisition strengthens our position as a leader in single-use bioprocessing technologies and extends our reach into downstream processes, where disposables are increasingly being adopted by biopharmaceutical manufacturers for the convenience, flexibility and cost advantages that they offer,” commented Repligen President and CEO Tony J. Hunt.

Repligen’s other downstream products include Protein A ligands for chromatography media and chromatography columns. The company currently offers the XCell ATF (Alternating Tangential Flow) for upstream processing. Other single-use TFF offerings include Pall’s Cadence TFF modules and Parker Dominick Hunter’s PROPOR hollow fiber filters.